Genetics may determine link between aspirin, colon cancer risk
the ONA take:
According to a new study published in the Journal of the American Medical Association (JAMA), researchers have found that a person's individual genetics may determine if a person will have a reduced risk of colon cancer from taking aspirin.
The association between taking aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) and colorectal cancer prevention is well known, but it is not understood why some people benefit from the agents and some do not.
Therefore, researchers from four countries sought to investigate whether there is an association between certain DNA variations and the protection that aspirin confers.
For the study, researchers analyzed the data of over 17,000 people from ten large studies. They identified 8,624 people who developed colorectal cancer and 8,553 people who did not.
Results showed that there was DNA evidence that 1 in 25 people do not benefit from aspirin. Researchers found that those people may actually have an increased risk of developing colorectal cancer if they take aspirin.
A person's individual genetics may determine if a person will have a reduced risk of colon cancer from taking aspirin.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|